Drug intelligence / Profile preview

Hemozink

Development stage: Unknown
Lead developer: Group Pharmaceutical
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral

Overview

Hemozink is an over-the-counter (OTC) nutritional supplement syrup developed by Group Pharmaceutical. The formulation is a combination of iron, zinc, protein, and multiple vitamins, categorized under the company's consumer health and multi-specialty portfolio. It is intended for use in addressing nutritional deficiencies and supporting general wellness, with specific applications in woman care and nutritional health. As a multi-component product, it provides essential minerals and proteins necessary for various physiological processes, including the synthesis of hemoglobin and the maintenance of enzymatic activities.

Brand names: Hemozink
Other names: Hemozink

Beyond the preview

Go deeper on Hemozink.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemozink.

Explore the full profile